AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) Receives $12.00 Average PT from Brokerages

AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) has been assigned a consensus rating of “Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $12.00.

A number of analysts recently weighed in on AMRX shares. JPMorgan Chase & Co. increased their price objective on shares of AMNEAL PHARMACEUTICALS from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday. The Goldman Sachs Group started coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They issued a “buy” rating and a $12.00 price objective on the stock.

AMNEAL PHARMACEUTICALS Stock Performance

AMNEAL PHARMACEUTICALS stock opened at $9.81 on Tuesday. AMNEAL PHARMACEUTICALS has a 1 year low of $6.68 and a 1 year high of $10.34. The firm’s 50-day moving average is $8.94 and its 200-day moving average is $8.22. The company has a market cap of $3.08 billion, a P/E ratio of 981.98 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, sell-side analysts predict that AMNEAL PHARMACEUTICALS will post 0.53 earnings per share for the current year.

Insider Activity

In other AMNEAL PHARMACEUTICALS news, EVP Nikita Shah sold 6,340 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $9.50, for a total transaction of $60,230.00. Following the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,390,828.50. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the transaction, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. The trade was a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 609,206 shares of company stock worth $5,700,625 in the last 90 days. 26.56% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AMNEAL PHARMACEUTICALS

Several large investors have recently bought and sold shares of AMRX. Nuveen LLC acquired a new position in shares of AMNEAL PHARMACEUTICALS in the 1st quarter worth approximately $19,581,000. Rubric Capital Management LP grew its stake in shares of AMNEAL PHARMACEUTICALS by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after purchasing an additional 974,355 shares during the last quarter. Woodline Partners LP grew its stake in shares of AMNEAL PHARMACEUTICALS by 165.2% in the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company’s stock worth $12,604,000 after purchasing an additional 937,035 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of AMNEAL PHARMACEUTICALS by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock worth $132,092,000 after purchasing an additional 920,758 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of AMNEAL PHARMACEUTICALS by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock worth $21,759,000 after purchasing an additional 880,471 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

AMNEAL PHARMACEUTICALS Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.